The acquisition includes Valencia, Calif.-based Bioness’ six-device portfolio of peripheral nerve stimulation therapy technology sold in 40 countries worldwide, according to a March 31 release.
Bioness systems are designed to help patients regain mobility after a stroke, traumatic brain injury, multiple sclerosis and osteoarthritis.
The total addressable market for Bioness medical devices is estimated to be more than $8 billion. In 2020, Bioness generated approximately $40 million in revenue.
More articles on devices:
Spinal fusion ‘picking up steam’ at ASCs: 2 leaders discuss practice growth
Alphatec, NuVasive & SeaSpine: Key spine acquisitions in 2021
Why endoscopic spine surgery in the US lags behind Europe, Asia
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
